Survivorship-focused content at the American Society of Clinical Oncology (ASCO) 2022-2024 annual meetings.

L Lauren Rynar (Rush University Medical Center, Chicago, IL) S Sandra Naaman (Rush University Medical Center, Chicago, IL) B Benjamin Bates (3Rutgers Robert Wood Johnson Medical School, New Brunswick, United States) M Mercedes Castiel (Cancer Care Concierge, Pelham, NY) D Douglas E. Peterson (UConn Health, Farmington, CT) J Julien Vos (Amsterdam UMC, Amsterdam, Netherlands) I Imdat Eroglu (Gazi University School of Medicine, Department of Medical Oncology, Ankara, Turkey) J Joseph William McCollom (Parkview Cancer Institute, Fort Wayne, IN) D David H. Noyd (University of Washington, Seattle, WA) C Christine A. Garcia (NewYork-Presbyterian Hospital/Weill Cornell Medicine, New York, NY) N Nicole Agaronnik (1Dana-Farber Cancer Institute, Boston, United States) M Melinda Laine Hsu (University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH) K Kelley C. Wood (Select Medical, Mechanicsburg, PA) P Padmaja V. Mallidi (Blue Ridge Cancer Care - Roanoke Clinic, Roanoke, VA) R Rejin Kebudi (18Istanbul University, Oncology Institute, Istanbul, Türkiye) N Niharika Dixit (University of California, San Francisco, San Francisco, CA) L Larissa Nekhlyudov (Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA)

Abstract

1671 Background: Survivorship is a core component of comprehensive cancer care yet its representation in major oncology scientific meetings remains unclear. This study systematically evaluated survivorship-focused content presented over three years at the ASCO Annual Meetings for prevalence, characteristics, and thematic patterns. Methods: All abstracts presented at the ASCO Annual Meeting from 2022-2024 were obtained (N=8,928). Abstracts containing the root word “survivor” (e.g., survivor, survivors, survivorship) in the title, text, or submission category “Symptoms and Survivorship” were identified using an automated data-extraction tool. Each extracted abstract underwent structured review to determine relevance to survivorship and then mapped to domains of the Quality of Cancer Survivorship Framework. Two independent reviewers evaluated each abstract, with discrepancies resolved by consensus. Descriptive statistics were used to summarize abstract content. Results: A total of 568 abstracts from 2022-2024 contained the root word “survivor” in the title, text or the submission category, representing 6.4% of all presented abstracts. Prevalence of survivorship-focused abstracts increased modestly from 2.2% in 2022 to 4.1% in 2024. Reviewers identified 63.8% of the extracted abstracts as relevant to the survivorship care framework and abstracts most frequently addressed the survivorship domains of physical effects (28.3%) and contextual factors (14.6%). Additional analyses examined cancer type and stage studied (36.6% mixed, 19.5% breast; 55.2% cancer stage not specified), survivorship stage (45% not specified, 19.3% in curative treatment), study design (65.9% observational), and healthcare setting (58.2%). Conclusions: Despite a rapidly growing population of cancer survivors, survivorship-focused content at the ASCO Annual Meeting remained largely static between 2022 and 2024, highlighting a gap between emerging survivorship needs and representation within oncology research programming. Further, abstracts frequently failed to specify the study population or context, or reference specific implications to survivorship domains. This study establishes a reproducible benchmark for monitoring survivorship content and provides a scalable methodology for ongoing surveillance of future meeting abstracts. The abstraction method may have excluded relevant survivorship-focused content. These findings could guide ASCO educational planning committees as they refine strategies to strengthen and advance survivorship-focused content in future meetings, ensuring alignment with the evolving needs of the survivor community.

Article Details

Volume / Issue Vol. 44, Issue 16_suppl
Published June 01, 2026
Pages 1671-1671
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (17)

L

Lauren Rynar

Rush University Medical Center, Chicago, IL

S

Sandra Naaman

Rush University Medical Center, Chicago, IL

B

Benjamin Bates

3Rutgers Robert Wood Johnson Medical School, New Brunswick, United States

M

Mercedes Castiel

Cancer Care Concierge, Pelham, NY

D

Douglas E. Peterson

UConn Health, Farmington, CT

J

Julien Vos

Amsterdam UMC, Amsterdam, Netherlands

I

Imdat Eroglu

Gazi University School of Medicine, Department of Medical Oncology, Ankara, Turkey

J

Joseph William McCollom

Parkview Cancer Institute, Fort Wayne, IN

D

David H. Noyd

University of Washington, Seattle, WA

C

Christine A. Garcia

NewYork-Presbyterian Hospital/Weill Cornell Medicine, New York, NY

N

Nicole Agaronnik

1Dana-Farber Cancer Institute, Boston, United States

M

Melinda Laine Hsu

University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH

K

Kelley C. Wood

Select Medical, Mechanicsburg, PA

P

Padmaja V. Mallidi

Blue Ridge Cancer Care - Roanoke Clinic, Roanoke, VA

R

Rejin Kebudi

18Istanbul University, Oncology Institute, Istanbul, Türkiye

N

Niharika Dixit

University of California, San Francisco, San Francisco, CA

L

Larissa Nekhlyudov

Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA